Dendreon (NASDAQ:DNDN) has posted its results. The actual EPS and revenues don’t matter because of the stage of the company. But the company did lower its total expenses to $23.4 million. That compares to $26.3 million from Q2 2006 and roughly $28 million last quarter. Those expenses included options costs of $1.3 million and $2.9 million, respectively.
So the company slowed its cash burn rate, and that is what we wanted to see. Unfortunately the company made no new developments in the "highlights" or "disclosures." Unless the company announces some unexpected FDA developments or unless it announces a surprise partner, this one sounds like there could be a continued news vacuum.
Jon C. Ogg
August 7, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Take Charge of Your Retirement: Find the Right Financial Advisor For You in Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding professional guidance—and we’ve made it easier than ever for you to connect with the right financial advisor for your unique needs.
Here’s how it works:
1️ Answer a Few Simple Questions
Tell us a bit about your goals and preferences—it only takes a few minutes!
2️ Get Your Top Advisor Matches
This tool matches you with qualified advisors who specialize in helping people like you achieve financial success.
3️ Choose Your Best Fit
Review their profiles, schedule an introductory meeting, and select the advisor who feels right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.